BUFORD, Ga.--(BUSINESS WIRE)--Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced that it has signed an agreement with Core Oncology, Inc. for the distribution of TheraSeed® palladium-103 brachytherapy seeds. Under the terms of the agreement, Theragenics will be the exclusive palladium-103 seed supplier to Core for the treatment of prostate cancer in the U.S. and Canada. The term of the agreement is through November 30, 2011, and is automatically extended for additional one-year terms unless terminated by either party upon prior written notice.
